Perfusion seed cultures improve biopharmaceutical fed‐batch production capacity and product quality
- 15 February 2014
- journal article
- research article
- Published by Wiley in Biotechnology Progress
- Vol. 30 (3), 616-625
- https://doi.org/10.1002/btpr.1884
Abstract
Volumetric productivity and product quality are two key performance indicators for any biopharmaceutical cell culture process. In this work, we showed proof-of-concept for improving both through the use of alternating tangential flow perfusion seed cultures coupled with high-seed fed-batch production cultures. First, we optimized the perfusion N-1 stage, the seed train bioreactor stage immediately prior to the production bioreactor stage, to minimize the consumption of perfusion media for one CHO cell line and then successfully applied the optimized perfusion process to a different CHO cell line. Exponential growth was observed throughout the N-1 duration, reaching >40 × 106 vc/mL at the end of the perfusion N-1 stage. The cultures were subsequently split into high-seed (10 × 106 vc/mL) fed-batch production cultures. This strategy significantly shortened the culture duration. The high-seed fed-batch production processes for cell lines A and B reached 5 g/L titer in 12 days, while their respective low-seed processes reached the same titer in 17 days. The shortened production culture duration potentially generates a 30% increase in manufacturing capacity while yielding comparable product quality. When perfusion N-1 and high-seed fed-batch production were applied to cell line C, higher levels of the active protein were obtained, compared to the low-seed process. This, combined with correspondingly lower levels of the inactive species, can enhance the overall process yield for the active species. Using three different CHO cell lines, we showed that perfusion seed cultures can optimize capacity utilization and improve process efficiency by increasing volumetric productivity while maintaining or improving product quality. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 30:616–625, 2014Keywords
This publication has 31 references indexed in Scilit:
- Case Study: An accelerated 8‐day monoclonal antibody production process based on high seeding densitiesBiotechnology Progress, 2013
- Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactorsBiotechnology Progress, 2012
- CHO cells in biotechnology for production of recombinant proteins: current state and further potentialApplied Microbiology and Biotechnology, 2011
- Cell culture processes for monoclonal antibody productionmAbs, 2010
- Methods in mammalian cell line engineering: from random mutagenesis to sequence-specific approachesApplied Microbiology and Biotechnology, 2010
- Effects of Elevated pCO2 and Osmolality on Growth of CHO Cells and Production of Antibody-Fusion Protein B1: A Case StudyBiotechnology Progress, 2008
- Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo‐Fc expressing CHO cells cultivated in controlled batch bioreactorsBiotechnology & Bioengineering, 2006
- Process parameter shifting: Part II. Biphasic cultivation—A tool for enhancing the volumetric productivity of batch processes using Epo‐Fc expressing CHO cellsBiotechnology & Bioengineering, 2006
- Strategies for fed-batch cultivation of t-PA producing CHO cells: substitution of glucose and glutamine and rational design of culture mediumJournal of Biotechnology, 2004
- Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell culturesBiotechnology & Bioengineering, 2004